Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.49
(
-1.16%
)
Bitcoin
74,612.70
(
0.91%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 91920

Saturday, 03/26/2011 5:56:52 PM

Saturday, March 26, 2011 5:56:52 PM

Post# of 257253
BMY’s New-Drug Scorecard

One year ago (#msg-47502391), BMY gave EPS guidance for 2013 and listed its five most consequential new drugs. Here’s an update on each of them:

• Yervoy (ipilimumab): approved in US; MAA pending in EU.

• Eliquis (apixaban): approved in EU but no action to date in US for VTE prevention; submissions planned in US and EU for stroke prevention/AF.

• Dapagliflozin: FDA and EMA reviews in progress.

• Belatacept: FDA CRL issued May 2010; no action in EU as far as I know.

• Brivanib: in multiple phase-3 cancer trials.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today